Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report

Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Orouji, Elias, Ziegler, Birgit, Umansky, Viktor, Gebhardt, Christoffer, Utikal, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603073/
https://www.ncbi.nlm.nih.gov/pubmed/25526431
http://dx.doi.org/10.1097/MD.0000000000000161
_version_ 1782394856978513920
author Orouji, Elias
Ziegler, Birgit
Umansky, Viktor
Gebhardt, Christoffer
Utikal, Jochen
author_facet Orouji, Elias
Ziegler, Birgit
Umansky, Viktor
Gebhardt, Christoffer
Utikal, Jochen
author_sort Orouji, Elias
collection PubMed
description Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor ‘dabrafenib́ had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients’ leukocytes despite similar clinical efficacy in melanoma.
format Online
Article
Text
id pubmed-4603073
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46030732015-10-27 Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report Orouji, Elias Ziegler, Birgit Umansky, Viktor Gebhardt, Christoffer Utikal, Jochen Medicine (Baltimore) 5700 Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor ‘dabrafenib́ had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients’ leukocytes despite similar clinical efficacy in melanoma. Wolters Kluwer Health 2014-12-02 /pmc/articles/PMC4603073/ /pubmed/25526431 http://dx.doi.org/10.1097/MD.0000000000000161 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Orouji, Elias
Ziegler, Birgit
Umansky, Viktor
Gebhardt, Christoffer
Utikal, Jochen
Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title_full Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title_fullStr Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title_full_unstemmed Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title_short Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
title_sort leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603073/
https://www.ncbi.nlm.nih.gov/pubmed/25526431
http://dx.doi.org/10.1097/MD.0000000000000161
work_keys_str_mv AT oroujielias leukocytecountrestorationunderdabrafenibtreatmentinamelanomapatientwithvemurafenibinducedleukopeniacasereport
AT zieglerbirgit leukocytecountrestorationunderdabrafenibtreatmentinamelanomapatientwithvemurafenibinducedleukopeniacasereport
AT umanskyviktor leukocytecountrestorationunderdabrafenibtreatmentinamelanomapatientwithvemurafenibinducedleukopeniacasereport
AT gebhardtchristoffer leukocytecountrestorationunderdabrafenibtreatmentinamelanomapatientwithvemurafenibinducedleukopeniacasereport
AT utikaljochen leukocytecountrestorationunderdabrafenibtreatmentinamelanomapatientwithvemurafenibinducedleukopeniacasereport

Ejemplares similares